Welcome to our dedicated page for Nuvalent news (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent stock.
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company dedicated to improving human health by developing innovative small molecule therapeutics. The company uses advanced chemical insights to target biological mechanisms in new ways, focusing particularly on 'undruggable' targets. Nuvalent’s research aims to produce first-in-class and best-in-class small molecule therapies that significantly enhance patient outcomes.
Nuvalent is primarily engaged in creating precisely targeted therapies for cancer patients. Its novel approach seeks to surmount the limitations of existing treatments for clinically validated kinase targets. All of Nuvalent’s operations are based in the United States.
Key product candidates include:
- NVL-520: A brain-penetrant ROS1-selective inhibitor aimed at overcoming resistance to current ROS1 inhibitors and treating brain metastases in patients with ROS1-positive non-small cell lung cancer (NSCLC).
- NVL-655: An ALK-selective inhibitor designed to combat resistance and brain metastases in ALK-positive NSCLC.
- NVL-330: An HER2-selective inhibitor for treating HER2-mutant tumors, including those with HER2 exon 20 insertion mutations and brain metastases.
Nuvalent has made significant progress in its pipeline. Recently, the company presented preliminary proof-of-concept data for its ROS1 and ALK programs and advanced NVL-330 towards clinical development. Their latest financial results indicate a strong balance sheet, providing a cash runway into 2027.
On the partnership front, Nuvalent continues to attract support from both new and long-standing stockholders, as demonstrated by a successful $300 million public offering. The company is also expanding its team to support its global development plans and aims to submit new drug applications (NDAs) by 2026.
Recent significant milestones include:
- Initiation of the Phase 2 portion of the ALKOVE-1 study for NVL-655.
- FDA breakthrough therapy designation for NVL-520 and NVL-655 for specific NSCLC indications.
- Pipeline progress updates at major medical meetings.
In 2024, Nuvalent revealed its “OnTarget 2026” operating plan, aiming for its first potential product approval by 2026. This plan underscores Nuvalent’s commitment to delivering new treatments to patients as swiftly as possible.
Nuvalent, Inc. (Nasdaq: NUVL) has priced its underwritten public offering of 6,865,672 shares of Class A common stock at $33.50 per share, aiming for gross proceeds of approximately $230 million before expenses. The offering is expected to close on November 3, 2022, pending customary conditions. There is also a 30-day option for underwriters to buy an additional 1,029,850 shares. This offering is part of a shelf registration statement effective since August 16, 2022.
Nuvalent, Inc. (Nasdaq: NUVL) has launched an underwritten public offering of $200 million of Class A common stock, all offered by the company. A 30-day underwriters' option for an additional 15% of shares is also expected. The offering is subject to market conditions, and completion is uncertain. The offering is conducted under a shelf registration statement effective since August 16, 2022. Nuvalent specializes in targeted cancer therapies, focusing on kinase targets. J.P. Morgan and others are managing the offering.
Nuvalent reported preliminary Phase 1 data for NVL-520, a novel ROS1-selective inhibitor, at the EORTC-NCI-AACR Symposium. The treatment showed a favorable safety profile, with no dose-limiting toxicities or serious adverse events observed among 35 enrolled patients. Encouraging signs of efficacy were noted, with 48% of heavily pre-treated ROS1-positive NSCLC patients achieving partial responses. Notable response rates were 78% in patients with G2032R mutations and 73% in those with CNS metastases. NVL-520 aims to address challenges associated with existing treatments, including resistance mutations and CNS adverse effects.
Nuvalent, Inc. (Nasdaq: NUVL) announced new preclinical data for its selective kinase inhibitors NVL-330 and NVL-655 at the 34th EORTC-NCI-AACR symposium. NVL-330 targets HER2 exon 20 insertion mutations and demonstrates selectivity over wild-type EGFR, along with potential for treating brain metastases. Preclinical results indicate NVL-655's activity in ALK-positive tumors, overcoming resistance mutations. Nuvalent continues to advance its pipeline, showcasing significant therapeutic potential against hard-to-treat cancers.
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, will host a live webcast and conference call on October 28, 2022, at 8:30 a.m. EDT, to discuss preliminary Phase 1 data from the ARROS-1 clinical trial of NVL-520, alongside additional preclinical updates. This event coincides with the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain. Interested parties can access the webcast via Nuvalent’s investor page or by phone using the provided dial-in details.
On October 6, 2022, Nuvalent, Inc. (Nasdaq: NUVL) appointed Dr. Michael L. Meyers, an experienced oncologist and drug developer, to its Board of Directors. Dr. Meyers has been a Senior Clinical Advisor to Nuvalent since 2020 and brings a wealth of experience from his roles at Syndax Pharmaceuticals and Johnson & Johnson. His expertise is expected to enhance Nuvalent's capabilities as it advances its clinical programs, including NVL-520 and NVL-655, which target advanced ROS1-positive and ALK-positive non-small cell lung cancer. The company continues to position itself as a leader in oncology therapies.
Nuvalent, Inc. (Nasdaq: NUVL) announced it will present preliminary results from the ARROS-1 Phase 1/2 trial of NVL-520, aimed at treating advanced ROS1-positive non-small cell lung cancer (NSCLC), during the EORTC-NCI-AACR Symposium from October 26-28, 2022. Additional presentations will feature new preclinical data on NVL-655, an ALK-selective inhibitor, and the selection of NVL-330, targeting HER2 exon 20 insertion-positive tumors. The conference call is scheduled for October 28, 2022, to discuss these developments further.
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, announced CEO James Porter will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference on September 8, 2022, at 2:35 p.m. ET in Boston. Nuvalent focuses on developing targeted therapies for cancer, leveraging expertise in chemistry and drug design to combat resistance and minimize adverse effects. A live webcast of the event will be accessible on their website, with an archive available for 30 days.
Nuvalent, Inc. (Nasdaq: NUVL) announced significant pipeline progress in its press release dated August 10, 2022. The company plans to release preliminary dose escalation data from the ARROS-1 trial for NVL-520 in advanced ROS1-positive NSCLC in the second half of 2022. Nuvalent is also actively dosing patients in the ALKOVE-1 trial for NVL-655, targeting advanced ALK-positive NSCLC. Financially, as of June 30, 2022, Nuvalent had cash reserves of $257 million, with R&D expenses at $13.6 million and a net loss of $18.5 million for Q2 2022.
Nuvalent, Inc. (Nasdaq: NUVL) announced new preclinical data underscoring the promising profile of its ALK-selective inhibitor, NVL-655, along with a "Trial in Progress" poster for NVL-520, a ROS1-selective inhibitor. These presentations will occur at the IASLC 2022 World Conference on Lung Cancer in Vienna, August 6-9, 2022. NVL-655 has shown antitumor activity against resistant ALK mutations, while NVL-520 aims to treat advanced ROS1-positive cancers. Preliminary data from NVL-520's Phase 1/2 ARROS-1 study is expected in the latter half of 2022.
FAQ
What is the current stock price of Nuvalent (NUVL)?
What is the market cap of Nuvalent (NUVL)?
What is Nuvalent, Inc. specialized in?
What are the key product candidates of Nuvalent?
What recent achievements has Nuvalent made?
Where are Nuvalent's operations based?
What is the 'OnTarget 2026' operating plan?
How is Nuvalent funded for its operations?
What is the significance of FDA breakthrough therapy designation for NVL-520 and NVL-655?
What makes Nuvalent's approach unique?
How can one stay updated on Nuvalent’s progress?
What are the anticipated milestones for 2024?
